NEOsphere Biotechnologies
NEOsphere Biotechnologies advances induced proximity drug discovery with proteome-wide insight into compound activity and selectivity. Its deep proteomic profiling of nearly 10,000 molecular glue degraders to date across 11,000 proteins has revealed 300+ molecular glue targets, and the data feeds sphereOME, a foundation dataset mapping the accessible CRBN neosubstrate space. Built on this, sphereAI predicts compound–target degradation potential, even for targets without known degron motifs, and uses reinforcement learning to propose new selective, potent degraders.
